2:47 PM
 | 
Mar 12, 2018
 |  BC Extra  |  Company News

Sarepta to complete NDA submission for DMD candidate by YE18

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said on Monday that it plans to complete submission of a rolling NDA to FDA by year end for golodirsen (SRP-4053) to treat Duchenne muscular dystrophy amenable to exon 53 skipping. The company said it will seek accelerated approval for golodirsen based on an increase in...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >